The Immune Cell Engineering market is estimated to be valued at US$ 2.82 Bn in 2023 and is expected to exhibit a CAGR of 22% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Immune cell engineering involves the genetic and metabolic modification of immune cells like T cells, NK cells and dendritic cells for various therapeutic purposes. These engineered immune cells have shown promising results in cancer treatment and immunotherapy. They are being engineered to detect and destroy cancer cells more efficiently. Adoptive cell transfer therapy using CAR T-cells is a major application area. With increasing success of CAR T-cell therapies, their demand is growing rapidly.
The immune cell engineering market is expected to witness high growth over the forecast period owing to two major drivers-
High adoption in cancer treatment: CAR T-cell therapies have emerged as breakthrough treatments for blood cancers. The success of Kymriah and Yescarta in treating hematologic cancers has driven their adoption worldwide. This is fueling the demand for immune cell engineering.
Increasing investments in immunotherapies: With the success of checkpoint inhibitors, immunotherapy has become a major area of focus in drug development. Heavy investments are being made by biotech firms and pharma companies to develop novel immunotherapies using engineered immune cells. This growth in research funding and initiatives is supporting the immune cell engineering market growth.
Strength: Immune cell engineering offers promising solutions in immunotherapy. It allows development of engineered immune cells with enhanced specificity and cytotoxicity. Growing R&D efforts are expanding applications of engineered immune cells in cancer treatment.
Weakness: Manufacturing of engineered immune cells is complex and costly process. Significant technical challenges exist in engineering immune cells to impart desired therapeutic properties without losing natural functions. Regulatory approvals for clinical translation of engineered immune cells take considerable time.
Opportunity: Rising cancer incidence worldwide is driving demand for advanced immunotherapy options. Growing collaborations between industry and academia are aimed at clinical translation of novel cell engineering platforms. New technologies such as CRISPR are allowing precision engineering of immune cells.
Threats: Manufacturing capacities are yet to meet the rising clinical demands for engineered immune cells. Significant capital is required to build production infrastructure. Strict manufacturing regulations necessitate specialized facilities and expertise. Biosimilars threaten long-term profitability of high-cost engineered immune cell therapies.
The Global Immune Cell Engineering Market Size is expected to witness high growth, exhibiting CAGR of 22% over the forecast period, due to increasing demand for advanced immunotherapy options to treat cancer.
Regional analysis: North America dominates the global immune cell engineering market currently. Presence of leading market players and growing R&D expenditure on immunotherapy research drive market growth in the region. Asia Pacific is projected to be the fastest growing market owing to improving healthcare infrastructure, rising healthcare spending, and increasing government support for cell and gene therapy research.
Key players: Key players operating in the Immune Cell Engineering market include Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, Lonza Group, Miltenyi Biotec, Takara Bio Group, CellGenix GmbH, FUJIFILM Irvine Scientific, Agilent Technologies, Bio-Techne Corporation, Bio-Rad Laboratories, BD, Charles River Laboratories, Creative Bioarray, Sartorius AG, Novogene Corporation, AGC Biologics, Catalent, WuXi AppTec, ReachBio LLC. These players are focusing on developing novel cell engineering technologies to expand therapeutic applications of engineered immune cells.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it